First-in-Man, Dose-escalation Trial of C-met Kinase Inhibitor MSC2156119J in Subjects With Advanced Solid Tumors
Status:
Completed
Trial end date:
2015-10-31
Target enrollment:
Participant gender:
Summary
This is a an open-label, dose-escalation, first-in-man (FIM) study designed to explore
MSC2156119J, in subjects with advanced solid tumors who have not responded to previous
therapies or for whom no other therapies are available.
Subjects will be assigned one of the dosing regimens:
- Regimen 1: MSC2156119J once daily for 14 days, followed by 7 days with no treatment
(21-day cycle)
- Regimen 2: MSC2156119J three times per week (e.g., Days 1, 3, and 5) for three weeks
(21-day cycle)
- Regimen 3: MSC2156119J every day for three weeks (21-day cycle)